Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 9/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.47 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19219780 | 0.86 | NOTUM (0.66) | NOTUMMAPK1GAAALDH1A1SMN1; SMN2 | |
| SCHEMBL17545408 | 0.83 | NOTUM (0.45) | NOTUMMAPK1TRIM24 | |
| SCHEMBL7163398 | 0.79 | NOTUM (0.69) | NOTUMGAAHSD17B3ALDH1A1 | |
| SCHEMBL26777824 | 0.78 | NOTUM (0.63) | NOTUMGAAHSD17B3LMNA | |
| SCHEMBL19329573 | 0.78 | NOTUM (0.67) | NOTUM | |
| SCHEMBL2255409 | 0.78 | NOTUM (0.67) | NOTUMGAAHSD17B3NPC1 | |
| SCHEMBL21232729 | 0.75 | NOTUM (0.63) | NOTUMTRIM24ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL12781789 | 0.75 | NOTUM (0.63) | NOTUMGAAHSD17B3 | |
| SCHEMBL9471540 | 0.74 | NOTUM (0.62) | NOTUMMAPK1 | |
| SCHEMBL396037 | 0.73 | NOTUM (1.00) | NOTUMHSD17B3ALDH1A1SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170226090-A1 | INDOLINE SULFONAMIDE INHIBITORS OF DAPE AND NDM-1 AND USE OF THE SAME | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2017-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226090-A1 | INDOLINE SULFONAMIDE INHIBITORS OF DAPE AND NDM-1 AND USE OF THE SAME | INMT, MGAM, NNMT | NOTUM 581/4885MAPK1 2688/4885GAA 682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.